Latest research on Latuda

Lurasidone is an atypical antipsychotic developed by Dainippon Sumitomo Pharma. It was approved by the U.S. Food and Drug Administration (FDA) for treatment of schizophrenia on October 29, 2010 and is currently pending approval for the treatment of bipolar disorder in the United States. (Wikipedia)

Latest findings

Only one agent, lurasidone, has been approved by the United States Food and Drug Administration (FDA) as adjunctive treatment, combined with either Lithium or Valproate for acute bipolar I depression (Latuda [package insert], 2013). [source, 2015]
In fact, only one agent, lurasidone, has been approved by the FDA for adjunctive use (combined with Lithium or Valproate) for bipolar I depression (Latuda [package insert], 2013). [source, 2015]
ADA, Oxaliplatin, nilotinib, LS-194959, Estradiol benzoate, Nandrolone phenylpropionate, vilazodone, Azelastine Hydrochloride, Latuda and Paliperidone were purchased from Sigma-Aldrich. [source, 2015]
The selected drugs were nilotinib, LS-194959, ADA, Estradiol benzoate, Nandrolone phenylpropionate, vilazodone, Azelastine Hydrochloride, Latuda and Paliperidone. [source, 2015]